The effect of interferons on EMC-D virus pathogenesis in mice is highly dependent on strain, interferon type, and timing of administration.
Answers are grounded in this paper and cite their sources.
Variable IFN effects across mouse strains caution against clinical translation; leaves open optimal dosing and relevance for human studies.
Interferon (IFN) can either prevent or exacerbate the pathogenic effects of the diabetogenic variant of encephalomyocarditis (EMC-D) virus. The effect seen is dependent upon the mouse strain and the time of IFN administration. For example, IFN-alpha beta protects SWR/J but not ICR Swiss male mice against the diabetogenic effects of the virus. Administration of either IFN-alpha beta or the IFN-inducer poly(I):poly(C) 4 days post infection, results in an exacerbation of the infection in ICR Swiss and C57BL/6 male mice. Studies have been initiated to investigate the role of the IFN system in the pathogenesis of this virus infection. In this study IFNs or poly(I):poly(C) were administered to several mouse strains at 24 h before or 4 days after infection with EMC-D virus. The results of such treatment ranged from complete protection of the animals from the diabetogenic effects of the virus to exacerbation of the infection as reflected by the virus content in selected organs. The effect was dependent upon the mouse strain, the type of IFN, and the time of its administration in relation to virus infection.
No takes yet. Share an insight, caveat, or question.
Giron et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: